# argenx vs Boston Scientific: stocks compared

URL: https://funkfolio.com/compare/argx-vs-bsx

> argenx ($59.6B, P/E 32.9) and Boston Scientific ($62.4B, P/E 18.5) compared: size, valuation, margins, debt, cash and price change.

---

## argenx vs Boston Scientific

argenx (ARGX), health care, and Boston Scientific (BSX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Boston Scientific is worth $62.4B on the stock market and argenx $59.6B: Boston Scientific is valued at 5% more. argenx trades at 32.9 times earnings and Boston Scientific at 18.5; operating margins in their latest fiscal years were 25.4% and 18.0%. Over the past year argenx's share price has moved +3.53% and Boston Scientific's -56.0%.

### Key facts

- **argenx market value:** $59.6B
- **Boston Scientific market value:** $62.4B
- **argenx P/E:** 32.9
- **Boston Scientific P/E:** 18.5
- **argenx revenue:** $4.2B FY to 2025-12-31
- **Boston Scientific revenue:** $20.1B FY to 2025-12-31
- **Superinvestors holding both:** 0

Market values as of 18 Nov 2026, 05:03 UTC.

argenx vs Boston Scientific: every measure side by side

| Measure | argenx | Boston Scientific |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | Belgium | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $59.6B lower | $62.4B higher |
| Revenue | $4.2B lower | $20.1B higher |
| Earnings | $1.3B lower | $2.9B higher |
| Employees | 1,863 lower | 59,000 higher |
| Total assets | $8.7B lower | $43.7B higher |
| Valuation |  |  |
| P/E | 32.9 higher | 18.5 lower |
| P/S | 14.4 higher | 3.1 lower |
| P/B | — | 2.4 |
| Dividend yield | — | 0.00% |
| Profitability |  |  |
| Operating margin | 25.4% higher | 18.0% lower |
| Balance sheet |  |  |
| Net assets | $7.3B lower | $24.2B higher |
| Total liabilities | $1.4B lower | $19.2B higher |
| Total debt | — | $11.4B |
| Cash on hand | $3.5B higher | $2B lower |
| Price change |  |  |
| Today | -0.36% higher | -1.51% lower |
| 1 year | +3.53% higher | -56.0% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: argenx 101.9, Boston Scientific 42.3.

- argenx (ARGX)
- Boston Scientific (BSX)

argenx and Boston Scientific share prices over one year, rebased to 100: argenx ends at 101.9, Boston Scientific at 42.3.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | ARGX | BSX |
| --- | --- | --- |
| Nov 28, 2025 | 98.1 | 99.8 |
| Dec 31, 2025 | 90.5 | 93.7 |
| Jan 30, 2026 | 90.4 | 91.9 |
| Feb 27, 2026 | 82.5 | 75.5 |
| Mar 31, 2026 | 78.6 | 61.7 |
| Apr 30, 2026 | 84.1 | 56.6 |
| May 29, 2026 | 89.9 | 47.5 |
| Jun 30, 2026 | 99.8 | 41.9 |
| Jul 31, 2026 | 91.8 | 45.9 |
| Aug 31, 2026 | 111.0 | 47.5 |
| Sep 30, 2026 | 103.2 | 42.9 |
| Oct 30, 2026 | 96.0 | 41.3 |
| Nov 17, 2026 | 101.9 | 42.3 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (0)

None of the tracked investors.

#### argenx only (2)

- [Frank Sands](https://funkfolio.com/gurus/frank-sands) 1.0%
- [Ron Baron](https://funkfolio.com/gurus/ron-baron) 0.2%

#### Boston Scientific only (13)

- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 2.6%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) 2.3%
- [Primecap team](https://funkfolio.com/gurus/primecap) 1.6%
- [Steven Romick](https://funkfolio.com/gurus/steven-romick) 1.2%
- [Louis Bacon](https://funkfolio.com/gurus/louis-bacon) 0.8%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.7%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.6%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.4%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 0.3%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.3%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.3%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.1%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.1%

Percentages are each holding's share of that investor's reported portfolio. [Who owns ARGX](https://funkfolio.com/stock/ARGX/superinvestors) · [Who owns BSX](https://funkfolio.com/stock/BSX/superinvestors)

### More on argenx

- [argenx (ARGX) stock page](https://funkfolio.com/stock/ARGX)
- [argenx market cap](https://funkfolio.com/stock/ARGX/market-cap)
- [argenx revenue](https://funkfolio.com/stock/ARGX/revenue)
- [argenx P/E ratio](https://funkfolio.com/stock/ARGX/pe-ratio)
- [argenx operating margin](https://funkfolio.com/stock/ARGX/operating-margin)
- [argenx total debt](https://funkfolio.com/stock/ARGX/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Boston Scientific

- [Boston Scientific (BSX) stock page](https://funkfolio.com/stock/BSX)
- [Boston Scientific market cap](https://funkfolio.com/stock/BSX/market-cap)
- [Boston Scientific revenue](https://funkfolio.com/stock/BSX/revenue)
- [Boston Scientific P/E ratio](https://funkfolio.com/stock/BSX/pe-ratio)
- [Boston Scientific operating margin](https://funkfolio.com/stock/BSX/operating-margin)
- [Boston Scientific total debt](https://funkfolio.com/stock/BSX/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### argenx against its closest peers

- [argenx vs Edwards Lifesciences](https://funkfolio.com/compare/argx-vs-ew)
- [argenx vs Becton, Dickinson](https://funkfolio.com/compare/argx-vs-bdx)
- [argenx vs Cardinal Health](https://funkfolio.com/compare/argx-vs-cah)

#### Boston Scientific against its closest peers

- [Boston Scientific vs Cardinal Health](https://funkfolio.com/compare/bsx-vs-cah)
- [Boston Scientific vs Cencora](https://funkfolio.com/compare/bsx-vs-cor)
- [Boston Scientific vs Takeda Pharmaceutical](https://funkfolio.com/compare/bsx-vs-tak)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, argenx or Boston Scientific?**

By market value, Boston Scientific is the larger: $62.4B against $59.6B for argenx. By revenue in its latest fiscal year, Boston Scientific is the larger: $20.1B against $4.2B for argenx.

**Which has the higher P/E ratio?**

argenx: 32.9, against 18.5 for Boston Scientific. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

argenx: 25.4%, against 18.0% for Boston Scientific. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which superinvestors own both argenx and Boston Scientific?**

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold argenx and 13 hold Boston Scientific.

### Cite this page

Funkfolio, “argenx vs Boston Scientific”, data as of 18 November 2026. https://funkfolio.com/compare/argx-vs-bsx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
